Results 21 to 30 of about 145,467 (273)

Update on Extended Treatment for Venous Thromboembolism [PDF]

, 2018
The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge, Demelo-Rodríguez, Pablo, Llamazares-Mendo, Cristina, Marra, Alberto M, Peñaloza-Martínez, Eduardo, Proietti, Marco, Soria Fernández-Llamazares, Guillermo, Álvarez-Sala Walther, Luis   +7 more
core   +2 more sources

Warfarin and food, herbal or dietary supplement interactions: A systematic review

British Journal of Clinical Pharmacology, 2020
To present an updated overview on the safety of concurrent use of food, herbal or dietary supplement and warfarin.
C. S. S. Tan, Shaun Wen Huey Lee
semanticscholar   +1 more source

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Blood, 2018
Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid ...
V. Pengo, G. Denas, G. Zoppellaro, S. Jose, A. Hoxha, A. Ruffatti, L. Andreoli, A. Tincani, Caterina Cenci, D. Prisco, T. Fierro, P. Gresele, A. Cafolla, V. De Micheli, A. Ghirarduzzi, A. Tosetto, A. Falanga, I. Martinelli, S. Testa, D. Barcellona, M. Gerosa, A. Banzato   +21 more
semanticscholar   +1 more source

Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy

Thrombosis Journal, 2008
Introduction Atrial fibrillation affects an estimated 2.5 million Americans and incurs an average annual stroke risk of 4.5% per year. Despite warfarin reducing stroke risk by approximately 66%, prior studies show warfarin usage rates to be about 50 ...
Cavalcante Joao, Hamoud Ihab, Hudson Michael, Srivastava Ajay, Pai Chetan, Kaatz Scott   +5 more
doaj   +1 more source

Risk factors of ischemic stroke and subsequent outcome in hemodialysis patients [PDF]

, 2015
Background and purpose: End stage renal disease (ESRD) requiring hemodialysis (HD) carries up to a 10-fold greater risk of stroke than normal renal function. Knowledge concerning risk factors and management strategies derived from the general population
Dawson, Jesse, Findlay, Mark D., Fulton, Rachael L., Geddes, Colin C., Jardine, Alan G., Mark, Patrick B., Patel, Rajan K., Solbu, Marit D., Stevens, Kathryn K., Thomson, Peter C.   +9 more
core   +1 more source

Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran [PDF]

, 2015
© Otsui et al. 2015BACKGROUND: Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not required; however, a
Gorog, Diana A, Inoue, Nobutaka, Iwata, Sachiyo, Otsui, Kazunori, Ozawa, Toru, Suzuki, Atsushi, Takei, Asumi, Yamamoto, Junichiro, Yoshioka, Takayuki   +8 more
core   +2 more sources

Pharmacogenomic testing and its future in community pharmacy [PDF]

, 2020
Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core   +1 more source

Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease

JAMA Network Open, 2020
Key Points Question What is the role of warfarin in preventing ischemic strokes in patients with atrial fibrillation and end-stage renal disease? Findings This meta-analysis found that, although the current literature is only observational, warfarin use ...
M. Randhawa, Rohanlal Vishwanath, M. Rai, Ling Wang, A. K. Randhawa, G. Abela, Gaurav Dhar   +6 more
semanticscholar   +1 more source

Global deregulation of ginseng products may be a safety hazard to warfarin takers: solid evidence of ginseng-warfarin interaction

Scientific Reports, 2017
Recent global deregulation of ginseng as the table food raises our concern about the possible ginseng-warfarin interaction that could be life-threatening to patients who take warfarin for preventing fatal strokes and thromboembolism while using ginseng ...
Haiyan Dong, Ji Ma, Tao Li, Yingying Xiao, Ning Zheng, Jian Liu, Yu Gao, Jingwei Shao, Lee Jia   +8 more
doaj   +1 more source

Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model

ADMET and DMPK, 2021
Background: Pharmacokinetics of warfarin has not been described in our population. We derived the pharmacokinetic parameters from a validated pharmacokinetic-pharmacodynamic model. Methods: Patients receiving warfarin for at least 6 months were recruited
Kannan Sridharan, Rashed Al Banna, Aysha Husain   +2 more
doaj   +1 more source